IL311442A - Caix targeting il-12 fusion proteins and methods of use thereof - Google Patents

Caix targeting il-12 fusion proteins and methods of use thereof

Info

Publication number
IL311442A
IL311442A IL311442A IL31144224A IL311442A IL 311442 A IL311442 A IL 311442A IL 311442 A IL311442 A IL 311442A IL 31144224 A IL31144224 A IL 31144224A IL 311442 A IL311442 A IL 311442A
Authority
IL
Israel
Prior art keywords
amino acid
acid sequence
seq
hil
region
Prior art date
Application number
IL311442A
Other languages
English (en)
Hebrew (he)
Original Assignee
Bicara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicara Therapeutics Inc filed Critical Bicara Therapeutics Inc
Publication of IL311442A publication Critical patent/IL311442A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL311442A 2021-09-17 2022-09-16 Caix targeting il-12 fusion proteins and methods of use thereof IL311442A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245523P 2021-09-17 2021-09-17
PCT/US2022/043762 WO2023043978A2 (en) 2021-09-17 2022-09-16 Caix targeting il-12 fusion proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
IL311442A true IL311442A (en) 2024-05-01

Family

ID=85603506

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311442A IL311442A (en) 2021-09-17 2022-09-16 Caix targeting il-12 fusion proteins and methods of use thereof

Country Status (11)

Country Link
US (1) US20240392031A1 (cg-RX-API-DMAC7.html)
EP (1) EP4402158A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534468A (cg-RX-API-DMAC7.html)
KR (1) KR20240161081A (cg-RX-API-DMAC7.html)
CN (1) CN118369331A (cg-RX-API-DMAC7.html)
AU (1) AU2022345103A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232632A1 (cg-RX-API-DMAC7.html)
IL (1) IL311442A (cg-RX-API-DMAC7.html)
MX (1) MX2024003275A (cg-RX-API-DMAC7.html)
WO (1) WO2023043978A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202402034B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
CN115943210A (zh) 2020-01-20 2023-04-07 中外制药株式会社 配体结合融合蛋白
CN120035602A (zh) * 2022-06-17 2025-05-23 辉瑞公司 Il-12变体、抗-pd1抗体、融合蛋白及其用途
EP4739701A2 (en) * 2023-07-07 2026-05-13 Technische Universität München, in Vertretung des Freistaats Bayern Muteins of human interleukin 12
WO2025101133A1 (en) * 2023-11-10 2025-05-15 Agency For Science, Technology And Research Interleukin-12 variants and medical uses thereof
AU2024407051A1 (en) 2023-12-18 2026-07-30 Genzyme Corporation Il-12 loss of potency muteins
WO2025205534A1 (ja) * 2024-03-25 2025-10-02 積水メディカル株式会社 免疫測定方法、精度管理方法、標準試料及び免疫測定試薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1418184A1 (en) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
SI1966238T1 (sl) * 2005-12-30 2012-08-31 Merck Patent Gmbh Variante interlevkina-12P40 z izboljšano stabilnostjo
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
KR102884523B1 (ko) * 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
EP4037700A2 (en) * 2019-10-03 2022-08-10 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
JP7851612B2 (ja) * 2020-04-17 2026-04-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変il-12及びil-23ポリペプチドとその使用

Also Published As

Publication number Publication date
EP4402158A2 (en) 2024-07-24
ZA202402034B (en) 2025-06-25
EP4402158A4 (en) 2025-07-30
KR20240161081A (ko) 2024-11-12
WO2023043978A3 (en) 2023-09-28
AU2022345103A1 (en) 2024-03-28
WO2023043978A2 (en) 2023-03-23
US20240392031A1 (en) 2024-11-28
JP2024534468A (ja) 2024-09-20
MX2024003275A (es) 2024-05-07
CA3232632A1 (en) 2023-03-23
CN118369331A (zh) 2024-07-19

Similar Documents

Publication Publication Date Title
US20240392031A1 (en) Caix targeting il-12 fusion proteins and methods of use thereof
US20240287528A1 (en) Transglutaminase-mediated conjugation
TWI708788B (zh) 雙特異性抗體
EP3981793A1 (en) Ceacam5-resistant monoclonal antibody and preparation method thereof and use thereof
KR20210068487A (ko) 암을 치료하기 위한 신규 면역 사이토카인
CN110366561A (zh) 免疫应答的条件性激动剂
CN114075289A (zh) 抗cd73的抗体及其用途
US20230364255A1 (en) Transglutaminase-mediated conjugation
TW202328171A (zh) 靶向NKp46之經修飾之IL-2多肽及其用途
CN115916349B (zh) 针对Lewis Y的人源化抗体
CN115916250A (zh) 用于治疗表达cd90和cd326的癌症的组合物和方法
TW202016144A (zh) 包括cd3抗原結合片段之組成物及其用途
US20240228620A1 (en) Multispecific proteins and related methods
CN114651011B (zh) 靶向cd43的独特癌相关表位的单克隆抗体
WO2022116079A1 (zh) 一种抗ceacam5的人源化抗体及其制备方法和用途
Han et al. Monoclonal antibody 3H11 chimeric antigen receptors enhance T cell effector function and exhibit efficacy against gastric cancer
EP4725970A1 (en) Preparation and use of anti-gprc5d/bcma/cd3 trispecific antibody
WO2024109657A1 (zh) 抗ccr8抗体及其用途
HK40114345A (en) Caix targeting il-12 fusion proteins and methods of use thereof
US20250197507A1 (en) Cd161 binding proteins and related methods
TWI853396B (zh) 跨膜和盤繞結構域家族3的特異性抗體及其用途
US20250109203A1 (en) Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
WO2023088482A1 (en) Antibody mono-or multi-specific to ephrin type-a receptor 10, chimeric antigen receptor t-cell expressing the same and uses thereof
HK40121523A (en) Multispecific proteins and related methods
WO2024144806A1 (en) Antibodies specific to transmembrane and coiled-coil domain family 3 and uses thereof